TY - JOUR
T1 - Platelet amyloid precursor protein forms in AD
T2 - A peripheral diagnostic tool and a pharmacological target
AU - Padovani, Alessandro
AU - Borroni, Barbara
AU - Colciaghi, Francesca
AU - Pastorino, Lucia
AU - Archetti, Silvana
AU - Cottini, Elisabetta
AU - Caimi, Luigi
AU - Cattabeni, Flaminio
AU - Di Luca, Monica
PY - 2001
Y1 - 2001
N2 - Alzheimer Disease (AD) is characterized by the progressive deposition of β-amyloid in the parenchyma and cerebral microvasculature. The β-amyloid peptide derives from the metabolism of a larger precursor, Amyloid Precursor Protein (APP). This protein is present in central nervous system, but it is also expressed in peripheral tissues such as circulating cells. An alteration of the APP forms pattern in platelets has been recently reported in AD patients when compared to platelets both of control subjects or non AD patients (NADD). The accuracy of the assay to identify AD is high and decreased levels are found throughout the course of AD with a significant association with severity of symptoms. Moreover, a recent study has demonstrated that AD patients on donepezil (5 mg daily) for 4 weeks displayed two-fold increase in their APPr baseline levels up to normal range. Thus, platelet APP ratio (APPr) holds the potential to be a clinical marker, which might be of helpful and adjunctive value in the diagnosis of AD and in tracking the course of illness, also in the early stages when pharmacological treatment has the greatest potential of being effective.
AB - Alzheimer Disease (AD) is characterized by the progressive deposition of β-amyloid in the parenchyma and cerebral microvasculature. The β-amyloid peptide derives from the metabolism of a larger precursor, Amyloid Precursor Protein (APP). This protein is present in central nervous system, but it is also expressed in peripheral tissues such as circulating cells. An alteration of the APP forms pattern in platelets has been recently reported in AD patients when compared to platelets both of control subjects or non AD patients (NADD). The accuracy of the assay to identify AD is high and decreased levels are found throughout the course of AD with a significant association with severity of symptoms. Moreover, a recent study has demonstrated that AD patients on donepezil (5 mg daily) for 4 weeks displayed two-fold increase in their APPr baseline levels up to normal range. Thus, platelet APP ratio (APPr) holds the potential to be a clinical marker, which might be of helpful and adjunctive value in the diagnosis of AD and in tracking the course of illness, also in the early stages when pharmacological treatment has the greatest potential of being effective.
KW - Alzheimer
KW - Amyloid precursor protein
KW - Biomarker
KW - Platelets
UR - http://www.scopus.com/inward/record.url?scp=0034811885&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034811885&partnerID=8YFLogxK
U2 - 10.1016/S0047-6374(01)00315-3
DO - 10.1016/S0047-6374(01)00315-3
M3 - Article
C2 - 11589917
AN - SCOPUS:0034811885
VL - 122
SP - 1997
EP - 2004
JO - Mechanisms of Ageing and Development
JF - Mechanisms of Ageing and Development
SN - 0047-6374
IS - 16
ER -